EA200601471A1 - Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) - Google Patents

Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)

Info

Publication number
EA200601471A1
EA200601471A1 EA200601471A EA200601471A EA200601471A1 EA 200601471 A1 EA200601471 A1 EA 200601471A1 EA 200601471 A EA200601471 A EA 200601471A EA 200601471 A EA200601471 A EA 200601471A EA 200601471 A1 EA200601471 A1 EA 200601471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prevention
malances
options
variants
basis
Prior art date
Application number
EA200601471A
Other languages
English (en)
Inventor
Веереса Гудудуру
Джеймс Т. Далтон
Дуэйн Д. Миллер
Еунджу Хурх
Original Assignee
Зи Охайо Стэйт Юнивесити Рисеч Фаундейшн
Зи Юнивесити Оф Теннесси Рисеч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зи Охайо Стэйт Юнивесити Рисеч Фаундейшн, Зи Юнивесити Оф Теннесси Рисеч Фаундейшн filed Critical Зи Охайо Стэйт Юнивесити Рисеч Фаундейшн
Publication of EA200601471A1 publication Critical patent/EA200601471A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Предложены аналоги, проявляющие ингибирование пролиферации клеток. Включены также способы получения аналогов. Аналоги могут быть использованы для лечения злокачественных состояний, таких как рак простаты, молочной железы и яичников.
EA200601471A 2004-02-11 2005-02-11 Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) EA200601471A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54372404P 2004-02-11 2004-02-11
US55580304P 2004-03-24 2004-03-24
PCT/US2005/004759 WO2005086638A2 (en) 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof

Publications (1)

Publication Number Publication Date
EA200601471A1 true EA200601471A1 (ru) 2007-10-26

Family

ID=34976061

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601471A EA200601471A1 (ru) 2004-02-11 2005-02-11 Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)

Country Status (8)

Country Link
EP (1) EP1723127A4 (ru)
JP (1) JP2007522247A (ru)
AU (1) AU2005220705A1 (ru)
BR (1) BRPI0507612A (ru)
CA (1) CA2559333A1 (ru)
EA (1) EA200601471A1 (ru)
IL (1) IL177444A0 (ru)
WO (1) WO2005086638A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395146B1 (ko) * 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2014066613A2 (en) * 2012-10-26 2014-05-01 Zhejiang University Sphingolipid metabolite mimetics
WO2014145314A2 (en) * 2013-03-15 2014-09-18 Cancer Research Technology, Llc Methods and compositions for gamma-glutamyl cycle modulation
WO2023170024A1 (en) * 2022-03-11 2023-09-14 University Of Copenhagen Camk2 modulators and their use in medicine
CN115894398B (zh) * 2022-12-02 2024-03-12 青岛科技大学 一种含氟噻唑酰胺类杀虫杀螨剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058260T3 (es) * 1987-03-24 1994-11-01 Nippon Chemiphar Co Un proceso para la preparacion de un derivado del glicerol.
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
FR2678938B1 (fr) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa Derives de pyrrolidine, leur preparation et les medicaments les contenant.
FR2700168B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen

Also Published As

Publication number Publication date
WO2005086638A2 (en) 2005-09-22
CA2559333A1 (en) 2005-09-22
IL177444A0 (en) 2006-12-10
AU2005220705A1 (en) 2005-09-22
WO2005086638A3 (en) 2005-11-24
EP1723127A2 (en) 2006-11-22
EP1723127A4 (en) 2009-10-28
JP2007522247A (ja) 2007-08-09
BRPI0507612A (pt) 2007-07-03

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
HK1089153A1 (en) Proteasome inhibitors and methods of using the same
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
TWI367886B (en) Proteasome inhibitors and methods of using the same
ATE408412T1 (de) Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration
IN2012DN01964A (ru)
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
MY169330A (en) Method for inhibition of deubiquitinating activity
EA200601471A1 (ru) Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
MY162518A (en) Proteasome inhibitors and methods of using the same
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
EA201170127A1 (ru) АНТАГОНИСТЫ РНК, НАЦЕЛЕННЫЕ НА Hsp27
NZ597948A (en) Combinations for the treatment of diseases involving cell proliferation
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей